Homestead Advisers’s Boston Scientific BSX Stock Holding History

Homestead Advisers’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6M	Sell	552,062 -390,000	-41%	-$21.2M	0.59%	51
2026 Q1	$59.1M	Buy	942,062 +395,000	+72%	+$31.6M	1.59%	29
2025 Q4	$52.2M	Sell	547,062 -121,364	-18%	-$11.9M	1.38%	34
2025 Q3	$65.3M	Sell	668,426 -91,000	-12%	-$9.42M	1.55%	30
2025 Q2	$81.6M	Sell	759,426 -223,100	-23%	-$22.6M	1.93%	21
2025 Q1	$99.1M	Sell	982,526 -197,000	-17%	-$19.8M	2.43%	12
2024 Q4	$105M	Buy	1,179,526 +43,700	+4%	+$3.85M	2.54%	8
2024 Q3	$95.2M	Sell	1,135,826 -202,700	-15%	-$16M	2.26%	14
2024 Q2	$103M	Sell	1,338,526 -240,400	-15%	-$17.6M	2.54%	12
2024 Q1	$108M	Sell	1,578,926 -64,600	-4%	-$4.15M	2.54%	11
2023 Q4	$95M	Buy	1,643,526 +2,900	+0.2%	+$155K	2.43%	14
2023 Q3	$86.6M	Buy	1,640,626 +25,200	+2%	+$1.32M	2.41%	15
2023 Q2	$87.4M	Buy	1,615,426 +7,900	+0.5%	+$413K	2.32%	15
2023 Q1	$80.4M	Sell	1,607,526 -112,200	-7%	-$5.29M	2.24%	16
2022 Q4	$79.6M	Sell	1,719,726 -97,600	-5%	-$4.23M	2.12%	18
2022 Q3	$70.4M	Sell	1,817,326 -4,200	-0.2%	-$168K	2.13%	16
2022 Q2	$67.9M	Hold	1,821,526	–	–	1.92%	21
2022 Q1	$80.7M	Buy	1,821,526 +242,400	+15%	+$10.5M	1.98%	20
2021 Q4	$67.1M	Buy	1,579,126 +291,900	+23%	+$12.3M	1.54%	26
2021 Q3	$55.9M	Buy	1,287,226 +5,100	+0.4%	+$226K	1.36%	31
2021 Q2	$54.8M	Sell	1,282,126 -17,900	-1%	-$753K	1.27%	34
2021 Q1	$50.2M	Sell	1,300,026 -66,000	-5%	-$2.5M	1.2%	36
2020 Q4	$49.1M	Sell	1,366,026 -33,000	-2%	-$1.19M	1.21%	34
2020 Q3	$53.5M	Sell	1,399,026 -155,900	-10%	-$6.01M	1.46%	31
2020 Q2	$54.6M	Buy	1,554,926 +2,100	+0.1%	+$75.6K	1.4%	33
2020 Q1	$50.7M	Sell	1,552,826 -44,845	-3%	-$1.75M	1.49%	28
2019 Q4	$72.2M	Sell	1,597,671 -15,228	-0.9%	-$637K	1.51%	27
2019 Q3	$65.6M	Sell	1,612,899 -59,101	-4%	-$2.5M	1.32%	29
2019 Q2	$71.9M	Buy	1,672,000 +286,000	+21%	+$11M	1.36%	24
2019 Q1	$53.2M	Buy	+1,386,000	New	+$52.9M	0.99%	33

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Homestead Advisers's BSX Position: Q2 2026 in Review

Homestead Advisers reduced its Boston Scientific (BSX) stake by 41% in Q2 2026, selling an estimated $21.2M and leaving 552,062 shares worth $23.6M. The position accounts for 0.59% of the portfolio, ranked #51.

Homestead Advisers first reported a position in BSX in Q1 2019 and has held it in 30 quarters since. The position peaked at $108M in Q1 2024. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Homestead Advisers held 552,062 shares of Boston Scientific worth $23.6M as of Q2 2026.
Homestead Advisers sold 390,000 Boston Scientific shares in Q2 2026, an estimated $21.2M.
Boston Scientific made up 0.59% of Homestead Advisers's portfolio in Q2 2026, its #51 holding.
Homestead Advisers first reported a position in Boston Scientific in Q1 2019 and has held it in 30 quarters since.
Homestead Advisers's Boston Scientific position peaked at $108M in Q1 2024.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Homestead Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.